Reconciling differences between EUCAST 'breakpoint-defining doses' and UK national antimicrobial treatment guidelines.

Conor Jamieson, Sara E Boyd, Mandy Wootton, David M Livermore, Kieran Hand, Alasdair P Macgowan, Robin A Howe, BSAC Standing Committee on Antimicrobial Susceptibility Testing

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Conor JamiesonMedical Directorate, NHS England (Midlands), Birmingham, UK.

Sara E BoydDavid Price Evans Global Health and Infectious Disease Research Group, University of Liverpool, Institute of Systems, Molecular & Integrative Biology, William Henry Duncan Building, Liverpool L7 8TX, UK.ORCID 0000-0001-9935-5263

Mandy WoottonSpecialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, UK.ORCID 0000-0002-2227-3355

David M LivermoreNorwich Medical School, University of East Anglia, Floor 2, Bob Champion Research & Educational Building, James Watson Road, Norwich NR4 7UQ, UK.

Kieran HandMedical Directorate, NHS England, London, UK.

Alasdair P MacgowanAntimicrobial Reference Laboratory, North Bristol NHS Trust, Westbury-on Trym, Bristol, UK.

Robin A HoweSpecialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, UK.

BSAC Standing Committee on Antimicrobial Susceptibility Testing

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The British National Formulary and the NICE provide empirical treatment guidance for the management of various infections, including recommendations on antibiotic doses. In parallel, and for over 15 years, EUCAST has published details of the doses upon which their antimicrobial susceptibility breakpoints are predicated, termed here 'breakpoint-defining doses'. Recently, differences between these dosing recommendations have attracted attention, particularly since EUCAST introduced its 'susceptible, increased exposure' category of susceptibility. We discuss where and why these differences exist and how to reconcile them.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsPractice Guidelines as TopicHumansMicrobial Sensitivity TestsUnited KingdomAnti-Bacterial Agents

Identifiers

PMID42708708

DOI10.1093/jac/dkag315

PMCPMC13551605

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.